An AI-driven BioTECHNology company
An AI-driven BioTECHNology company
Zonula uses an AI platform to rapidly discover small molecules for the treatment of rheumatoid arthritis (RA). These small molecules target the fibroblasts in bone joints. This represents an entirely new approach to treating arthritis. The small molecules control the function of cell surface glycoproteins called cadherins. These molecules are inexpensive to manufacture and act in a different manner than existing RA drugs. Zonula holds US patents on several of these molecules.
Zonula has assembled a world-class team to perform discovery and development of RA targets and small molecules. The team has over a century of biotechnology experience in the areas of biology, chemistry, AI and drug development.